Market news

NEW HAVEN, Conn., August 13, 2026--Yarrow Bioscience reports second quarter 2026 financial results and provides a business update.

NEW HAVEN, Conn., July 27, 2026--Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the completion of its merger with VYNE Therapeutics Inc. ("VYNE"), and the previously announced private financings totaling approximately $200 million. The combined company will operate as Yarrow Bioscience, Inc., with its shares expected to begin trading on the N

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its previously announced special cash dividend (the “Cash Dividend”), declared in connection with the terms and conditions of the Agreement and Plan of Merger and Reorganization, entered into on December 17, 2025, as amended (the “Merger Agreement”), with Yarrow Bioscience, Inc. (“Yarrow”) and Yellow Merger Sub Corp., was distributed, in cash, on July 23, 2026 to VYNE’

Aggregate cash dividend of $17.3 million, or approximately $0.40242 per shareNEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of Directors has approved a reverse stock split of VYNE’s common stock at a ratio of 1-for-50 in connection with the anticipated closing of the proposed merger (the “Merger”) with Yarrow Bioscience, Inc. (“Yarrow”). The reverse stock split was previously approved by VYNE’s stockholde

VYNE Therapeutics (VYNE) approved a 1-for-50 reverse stock split ahead of its planned merger with Ya

Gainers VYNE Therapeutics (NASDAQ:VYNE) stock increased by 17.9% to $0.79 during Friday's pre-market session. The company's market cap stands at $22.4 million. WORK Medical Tech Gr (NASDAQ:WOK) shares

Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per shareNEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of Directors has declared a special cash dividend (the “Cash Dividend”) in connection with the previously announced merger (the “Merger”) with Yarrow Bioscience, Inc. (“Yarrow”) pursuant to the Agreement and Plan of Merger and Reorganization, dated December 17, 2025 (as amen